

# ESHB 1879

## Prescription drug utilization management (R 2019-11)

~~WAC 284-43-0160: Definitions~~

~~WAC 284-43-2020: Drug Utilization Review-Generally.~~

~~WAC 284-2021: Prescription drug utilization management exception and substitution process.~~

~~WAC 284-43-2022: Time frame for exception and substitution request determinations.~~

~~WAC 284-43-5080: Prescription drug benefit design.~~

~~WAC 284-43-5100: Formulary changes.~~

~~WAC 284-43-5170: Prescription drug benefit disclosures.~~

## Consolidated health care rulemaking (R 2020-13)

### WAC 284-43-0160:

Definitions

(4) "Clinical review criteria"  
(38) "Step therapy protocol"  
(40) "Substitute Drug"

### WAC 284-43-2000:

Health care services utilization review-Generally.

### WAC 284-43-7100:

Required disclosures

(1b) protected individual  
(3) adverse benefit decision

R 2020 13 also amends WACs 284 43 5642, 5935, 5940, 5950, 5960, 5965, 5970, 5980, 7000, 7010, 7020, 7040, 7060, 7080, and 7120.

# SSB 5889

## Confidential communications (R 2019-03)

~~WAC 284-04-510: Right to limit disclosure of health information~~

~~WAC 284-43-2000: Health-care services utilization review-Generally.~~

~~WAC 284-43-2050: Prior authorization processes~~

~~WAC 284-43-3070: Notice and explanation of adverse benefit determination—General requirements.~~

~~WAC: 284-43-4040: Procedures for review and appeal of adverse determinations.~~

~~WAC 284-43-7100: Required disclosures~~